Activated tyrosine kinases in gastrointestinal stromal tumor with loss of KIT oncoprotein expression

Oncogenic KIT or PDGFRA receptor tyrosine kinase (TK) mutations are compelling therapeutic targets in gastrointestinal stromal tumors (GISTs), and the KIT/PDGFRA kinase inhibitor, imatinib, is the standard of care for patients with metastatic GIST. However, approximately 10% of KIT-positive GIST met...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cell Cycle
Главные авторы: Tu, Yuqing, Zuo, Rui, Ni, Nan, Eilers, Grant, Wu, Duolin, Pei, Yuting, Nie, Zuoming, Wu, Yeqing, Wu, Yuehong, Ou, Wen-Bin
Формат: Artigo
Язык:Inglês
Опубликовано: Taylor & Francis 2018
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6300111/
https://ncbi.nlm.nih.gov/pubmed/30488756
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2018.1553335
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы